Sympleitope connects our drug candidate functionality with antibody design; it is our proprietary approach to epitope screening and selection.
We believe that epitope diversity is critical and that antibodies targeting different epitopes may “turn on” or “turn off” different immunological function. Accordingly, we developed proprietary in vitro systems to interrogate the pharmacological and biological attributes of antibodies binding to distinct epitopes. We can generate both agonist and antagonist antibodies for both activating and inhibitory targets. Our first drug candidates are already demonstrating these differentiating insights.